504169896 01/09/2017

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4216574

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the ASSIGNEE'S NAME FROM BRI BIOPHARMACEUTICAL RESEACH INC. TO BRI BIOPHARMACEUTICAL RESEARCH INC. previously recorded on Reel 040537 Frame 0378. Assignor(s) hereby confirms the ASSIGNMENT.

CONVEYING PARTY DATA

Name	Execution Date
XIAOYUN LIU	08/15/2005

RECEIVING PARTY DATA

Name:	BRI BIOPHARMACEUTICAL RESEARCH INC.	
Street Address:	101-8898 HEATHER STREET	
City:	VANCOUVER	
State/Country:	CANADA	
Postal Code:	V6P 3S8	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	14380924

CORRESPONDENCE DATA

Fax Number: (703)519-9958

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7035199951

Email: docket@dcpatent.com

DITTHAVONG & STEINER, P.C. Correspondent Name:

Address Line 1: 44 CANAL CENTER PLAZA SUITE 322

Address Line 4: ALEXANDRIA, VIRGINIA 22314

ATTORNEY DOCKET NUMBER:	P6678US03
NAME OF SUBMITTER:	MICHAEL B. FARBER
SIGNATURE:	/Michael B. Farber/
DATE SIGNED:	01/09/2017

Total Attachments: 2

source=1023-007-PR_P6678US03_CorrectiveAssignment1_filed#page1.tif source=1023-007-PR P6678US03 CorrectiveAssignment1 filed#page2.tif

PATENT REEL: 041306 FRAME: 0737 504169896

504125382 12/06/2016

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4172052

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
XIAOYUN LIU	08/15/2005

RECEIVING PARTY DATA

Name:	BRI BIOPHARMACEUTICAL RESEACH INC.	
Street Address:	101-8898 HEATHER STREET	
City:	VANCOUVER	
State/Country:	CANADA	
Postal Code:	V6P 3S8	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	14380924

CORRESPONDENCE DATA

Fax Number: (703)519-9958

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7035199951

Email: docket@dcpatent.com

Correspondent Name: DITTHAVONG & STEINER, P.C.

Address Line 1: 44 CANAL CENTER PLAZA SUITE 322

Address Line 4: ALEXANDRIA, VIRGINIA 22314

ATTORNEY DOCKET NUMBER:	P6678US03
NAME OF SUBMITTER:	MICHAEL B. FARBER
SIGNATURE:	/Michael B. Farber/
DATE SIGNED:	12/06/2016

Total Attachments: 1

source=1023-007-PR_P6678US03_EmploymentAgreement_filed#page1.tif

PATENT REEL: 041306 FRAME: 0738 Biognalytical Biopharmaceutics & Drug Discovery

August 15, 2005

Tina Xiaoyun Liu 7591 Osler Street Vancouver, BC V6P 4C8

Dear Tina,

#101-8898 Heather Street Vancouver, B.C. Canada V6P 3S8 Tel: (604) 432-9237 Fax: (604) 432-9239 www.briphams.com

CERTIFIED A TRUE COPY

of Original Document Dated at Vancouver, British Columbia This & Eday of December 120/6

CAROLYNNE Æ MAGUIRE NOTARY PUBLIC 8528 GRANVILLE STREET VANCOUVER, B.C. V6P 4Z7 TEL: (604) 266-8970

On behalf of BRI Biopharmaceutical Research Inc. (BRI), I am pleased to provide you this letter of offer for employment of the Research Scientist position. The starting salary for this position will be \$60,000 per annum and your first day of work is on August 15, 2005. Periodic performance review will be performed at 3-months, 6-months, 9-months and 12-months. Salary might be adjusted at the time of the review based on the performance. This position is subjected to a 6 months probation period. In addition to the base salary, BRI also offers extended health benefit and yearly profit sharing performance bonus. Preference shares are offered to key individuals after their probation period.

During the probation period, you will be acting in the position on an interim basis and BRI is committed to provide you opportunities to mutually review your progress during this period. A copy of the job description for the position is attached for your record.

A copy of BRI's Employment Manual listed with BRI's company policy is also provided. I hope to point out that section 2.0 "Confidentiality and Inventions" is very important, as maintaining the confidential nature of the way we do business and what our business includes is critical. In addition, it is a requirement for all employees to understand and to agree that all discoveries, inventions, or intellectual property to be made in the course of or as a result of his or her employment of BRI shall vest in and be the exclusive property of BRI.

You will find two copies of this letter enclosed. The first is for your records, the second is to be signed by you to acknowledge your acceptance of employment and to indicate your agreement with the terms outlined in this letter.

Please return the signed copy to me at your earliest convenience.

Yours truly.

Clara Faan

VP Business Development / COO

Please sign below to indicate your acceptance of the terms outlined above and in the Agreement.

Name Like

Date

PATENT REEL: 041306 FRAME: 0739

RECORDED: 01/09/2017